Founded in 1999, Banook Group is a global provider of technology services, addressing Tier-1 Pharma and CROs. Historically specialized in Cardiac Safety, Banook has extended its capabilities in Central Imaging and eCOA with the acquisitions of Keosys and B.Reserarch in 2024

Banook Group centralizes and analyses medical data to assess drug safety and efficacy during clinical trials from early phases to late phases. Clinical data is collected and transferred to Banook’s 100% proprietary Clinical Trial Management System (CTMS), Atrium

On top of its technological solution, Banook relies on a pool of world-renowned Key Opinion Leaders (KOLs), which ensure quality driven and controlled services. The Group has direct implementations in Europe, US, Canada and Australia

In November 2023, Motion Equity Partners invested in Banook Group alongside Management, with the ambition to building a leading global technology services provider for clinical trials by expanding expertise range and international footprint.

Status

Current portfolio

Date of investment

2023

Website

banookgroup.com

BACK TO PORTFOLIO
20

Revenue

120

People

6

Offices accross the world

25

Of experience

“After a successful transitional phase, we are now ready to deploy our development strategy. The challenge of the upcoming years will be to reinforce our international expansion, with a strategic focus on North America, the world’s leading market. Motion Equity Partners has firmly established itself as the ideal partner to boost this next phase of our ambitious growth.”

Alexandre Durand-SalmonCEO